Characterization of preclinical models of prostate cancer using PET-based molecular imaging
- PMID: 19280188
- DOI: 10.1007/s00259-009-1091-3
Characterization of preclinical models of prostate cancer using PET-based molecular imaging
Abstract
Purpose: Transgenic adenocarcinoma of the mouse prostate (TRAMP) mice spontaneously develop hormone-dependent and hormone-independent prostate cancer (PC) that potentially resembles the human pathological condition. The aim of the study was to validate PET imaging as a reliable tool for in vivo assessment of disease biology and progression in TRAMP mice using radioligands routinely applied in clinical practice: [(18)F]FDG and [(11)C]choline.
Methods: Six TRAMP mice were longitudinally evaluated starting at week 11 of age to visualize PC development and progression. The time frame and imaging pattern of PC lesions were subsequently confirmed on an additional group of five mice.
Results: PET and [(18)F]FDG allowed detection of PC lesions starting from 23 weeks of age. [(11)C]Choline was clearly taken up only by TRAMP mice carrying neuroendocrine lesions, as revealed by post-mortem histological evaluation.
Conclusion: PET-based molecular imaging represents a state-of-the-art tool for the in vivo monitoring and metabolic characterization of PC development, progression and differentiation in the TRAMP model.
Similar articles
-
Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models.J Nucl Med. 2011 Oct;52(10):1654-63. doi: 10.2967/jnumed.110.086702. Epub 2011 Aug 22. J Nucl Med. 2011. PMID: 21859811
-
Hyperpolarized [1-13C]dehydroascorbate MR spectroscopy in a murine model of prostate cancer: comparison with 18F-FDG PET.J Nucl Med. 2013 Jun;54(6):922-8. doi: 10.2967/jnumed.112.115402. Epub 2013 Apr 10. J Nucl Med. 2013. PMID: 23575993 Free PMC article.
-
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003
-
Positron emission tomography for prostate, bladder, and renal cancer.Semin Nucl Med. 2004 Oct;34(4):274-92. doi: 10.1053/j.semnuclmed.2004.06.004. Semin Nucl Med. 2004. PMID: 15493005 Review.
-
Evaluation of Prostate Cancer with 11C- and 18F-Choline PET/CT: Diagnosis and Initial Staging.J Nucl Med. 2016 Oct;57(Suppl 3):38S-42S. doi: 10.2967/jnumed.115.169748. J Nucl Med. 2016. PMID: 27694169 Review.
Cited by
-
Preclinical Imaging of Prostate Cancer.Semin Nucl Med. 2023 Sep;53(5):644-662. doi: 10.1053/j.semnuclmed.2023.02.002. Epub 2023 Mar 5. Semin Nucl Med. 2023. PMID: 36882335 Free PMC article. Review.
-
Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.Mol Imaging Biol. 2013 Apr;15(2):175-85. doi: 10.1007/s11307-012-0588-5. Mol Imaging Biol. 2013. PMID: 22875335 Free PMC article.
-
Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1257-66. doi: 10.1007/s00259-011-1775-3. Epub 2011 Mar 23. Eur J Nucl Med Mol Imaging. 2011. PMID: 21431398 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical